Widespread Beta-Lactamase Resistance Genes Pose Growing Threat Across One Health Domains in the US

Babafela Awosile, DVM, MVSc, PhD, DACVPM Image credits: LinkedIn A comprehensive review of research underscores the widespread distribution of beta-lactamase resistance genes in Enterobacteriaceae across human, animal, and environmental sources in the United States. The study, which analyzed 335 articles published between 1981 and April 2022, provides critical insights into the molecular epidemiology of these […]

Estimating the AUC for Vancomycin Using Non Trapezoidal Equations

In the first part of the interview with Msdi, he discussed AUC-based monitoring for vancomycin and its adoption by institutions and its value in dosing. (See the article below.)  Read more: Looking at the Slow Adoption of AUC-Based Monitoring for Vancomycin In this segment, Msdi talks about using a unique approach that estimates the AUC […]

Do We Have New Data for Optimal Treatments of Candida-Related Prosthetic Joint Infections?

Prosthetic joint infections (PJIs) are among the most common complications of arthroplasties. Most PJIs are caused by bacteria and most commonly by Staphylococcus species, whereas only 1% to 2% are caused by fungi.1 Among these rare fungal PJIs, Candida species are the most isolated pathogens, with Candida albicans being the most prevalent, followed by non–C […]

Exploiting Zinc Limitation to Combat Carbapenem-Resistant Bacteria

Megan M Tu, PhD Candidate, McMaster University Image credits: LinkedIn Carbapenems, the last line of defense against serious bacterial infections, are increasingly ineffective against pathogens that produce metallo-β-lactamases (MBLs) such as VIM-2. These enzymes enable bacteria to resist carbapenem treatment, and there are currently no approved inhibitors targeting these enzymes in clinical settings. Although, recent […]

Looking at the Slow Adoption of AUC-Based Monitoring for Vancomycin

The development of the AUC-based vancomycin monitoring guidelines published in 2020 by the Infectious Diseases Society of America provided an updated foundation for clinicians and institutions to begin to utilize it, but there is a lot of nuance that needs to be considered when utilizing it. Implementation of AUC-based vancomycin monitoring nationwide is moving in […]

Targeting C difficile with Oxygen-Based Therapy

LPOXY Therapeutics, Inc has acquired key assets from Xeno Biosciences Inc to advance its therapy, SIDIPREV, aimed at preventing Clostridioides difficile (C difficile) infections in hospitalized patients. The acquisition includes regulatory filings, FDA correspondence, CMC data, intellectual property, and Phase I and Ib clinical trial data confirming the safety of the active pharmaceutical ingredient. This […]

Another Case of Shorter Is Better?

The optimal duration of antibiotic therapy for Streptococcus pneumoniae bacteremia remains a topic of debate in clinical practice. The mortality rate of bacteremia associated with a pneumococcal infection ranges from 6% to 20%.1 Balancing effective treatment with the need to minimize antibiotic exposure is critical, as prolonged courses can contribute to increased risk of Clostridioides […]

Treatment With Ziresovir in Infants

The fall and winter months signal an increase in viral infections circulating among children and families, including influenza, COVID-19, and respiratory syncytial virus (RSV). Although RSV is a public health concern for individuals of all ages, infants and toddlers, especially those born prematurely or with compromised immune systems, and older individuals have particular vulnerability to […]

Top 5 Infectious Disease News Stories Week of January 4-10

Entering Peak Norovirus Season as Cases Rise Across the US Norovirus cases have risen sharply across the US, with more than 22% of tests returning positive as of late December 2024, a significant increase from the previous year. The CDC reported 495 outbreaks during the 2024–2025 season, up from 363 in the same period in […]